Publications by authors named "Shuang-Ming Lin"
Development of a staging system for hepatoid adenocarcinoma of the stomach based on multicenter data: A retrospective cohort study: A Staging System for Hepatoid Adenocarcinoma of the Stomach.
Int J Surg
September 2024
Background: Hepatoid adenocarcinoma of the stomach (HAS) is a rare subtype of gastric cancer (GC) with a poor prognosis. Furthermore, the current pathological staging system for HAS does not distinguish it from that for common gastric cancer (CGC).
Methods: The clinicopathological data of 251 patients with primary HAS who underwent radical surgery at 14 centers in China from April 2004 to December 2019 and 5082 patients with primary CGC who underwent radical surgery at 2 centers during the same period were retrospectively analyzed.
Long-term prognostic benefit of adjuvant chemotherapy for patients with hepatoid adenocarcinoma of the stomach after radical resection: A national multicenter study.
Eur J Surg Oncol
November 2023
Background: There is no consensus on whether adjuvant chemotherapy (AC) is effective for hepatoid adenocarcinoma of the stomach (HAS). The aim of this study was to investigate the relationship between AC and the long-term prognosis of patients with HAS.
Methods: The clinicopathological data of 239 patients with primary HAS who underwent radical surgery from April 1, 2004 to December 31, 2019 in 14 centers in China were retrospectively analyzed.
Background: An accurate recurrence risk assessment system and surveillance strategy for hepatoid adenocarcinoma of the stomach (HAS) remain poorly defined. This study aimed to develop a nomogram to predict postoperative recurrence of HAS and guide individually tailored surveillance strategies.
Methods: The study enrolled all patients with primary HAS who had undergone curative-intent resection at 14 institutions from 2004 to 2019.
Importance: Few studies have examined the clinicopathological characteristics and prognoses of patients with hepatoid adenocarcinoma of the stomach (HAS).
Objective: To explore the clinicopathological characteristics and prognoses of patients with HAS and develop a nomogram to predict overall survival (OS).
Design, Setting, And Participants: This prognostic study involved a retrospective analysis of data from 315 patients who received a diagnosis of primary HAS between April 1, 2004, and December 31, 2019, at 14 centers in China.
Article Synopsis
- The study assessed the survival rates and recurrence patterns of remnant gastric cancer (RGC) after radical surgery, analyzing data from 298 patients to improve follow-up strategies.
- Findings revealed a 5-year overall survival rate of 41.2% and a 5-year disease-specific survival rate of 45.8%, with conditional survival rates increasing significantly for patients who had already survived 5 years.
- Most recurrences occurred within the first 3 years post-surgery, mainly influenced by the American Joint Committee on Cancer (AJCC) stage, leading to the development of a follow-up model tailored for RGC patients based on their cancer stage.
Background: Remnant gastric cancer (RGC) is a rare malignant tumor with poor prognosis. There is no universally accepted prognostic model for RGC.
Methods: We analyzed data for 253 RGC patients who underwent radical gastrectomy from 6 centers.